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Abstract
Background: Our ultimate goal is to detect the entire human microbiome, in health and in disease, in a single
reaction tube, and employing only commercially available reagents. To that end, we adapted molecular inversion
probes to detect bacteria using solely a massively multiplex molecular technology. This molecular probe
technology does not require growth of the bacteria in culture. Rather, the molecular probe technology requires
only a sequence of forty sequential bases unique to the genome of the bacterium of interest. In this
communication, we report the first results of employing our molecular probes to detect bacteria in clinical
samples.
Results: While the assay on Affymetrix GenFlex Tag16K arrays allows the multiplexing of the detection of the
bacteria in each clinical sample, one Affymetrix GenFlex Tag16K array must be used for each clinical sample. To
multiplex the clinical samples, we introduce a second, independent assay for the molecular probes employing
Sequencing by Oligonucleotide Ligation and Detection. By adding one unique oligonucleotide barcode for each
clinical sample, we combine the samples after processing, but before sequencing, and sequence them together.
Conclusions: Overall, we have employed 192 molecular probes representing 40 bacteria to detect the bacteria in
twenty-one vaginal swabs as assessed by the Affymetrix GenFlex Tag16K assay and fourteen of those by the
Sequencing by Oligonucleotide Ligation and Detection assay. The correlations among the assays were excellent.
Background
The Human Microbiome Project has taken a metage-
nomic approach to identifying the bacteria in a wide
variety of sites on and in the human body because the
substantial majority of these bacteria have not been
grown in culture [e.g.,[1]. Second generation DNA
sequencing on this level presents a formidable infor-
matics challenge. It is unlikely that such sequencing will
be useful for individual investigators and clinical diag-
nostics. Therefore, the challenge is to detect each bac-
terium in a mixture when all that is known about the
bacterium is a partial genome sequence.
In a previous publication [2], we presented our adap-
tion of molecular inversion probes [MIP; [3] to detect
bacteria using a massively multiplex molecular technol-
ogy. MIP technology was developed, in large part, to
discover and assay single nucleotide polymorphisms in
human DNA [4]. The human genome is diploid. Bacter-
ial genomes are haploid, and, therefore, the background
for molecular probe technology is significantly lower.
Because of this important difference, we simplified the
method by dispensing with the “inversion”.
Our method requires only a sequence of forty sequen-
tial bases unique to the bacterial genome of interest,
such as derived from the sequences produced by the
Human Microbiome Project. All necessary reagents are
commercially available, including an Affymetrix GenFlex
Tag16K array v2 (Tag4 array). Whereas we reported
previously the results of employing the molecular probes
with simulated clinical samples (artificial mixtures of
bacterial genomic DNAs made to resemble clinical sam-
ples), we report now the results with a set of clinical
samples: swabs of the vaginal epithelium.
While the assay on Tag4 arrays allows the multiplex-
ing of the detection of the bacteria in each clinical sam-
ple, nevertheless, one Tag4 array must be used for each
sample. To multiplex the clinical samples, we introduce
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employing Sequencing by Oligonucleotide Ligation and
Detection (SOLiD). All reagents are also commercially
available. By adding one unique oligonucleotide barcode
for each clinical sample, we combine the molecular
probes after processing each sample, but before sequen-
cing, and SOLiD sequence them all together. Overall,
we have employed 192 molecular probes representing
40 bacteria to detect the bacteria in twenty-one vaginal
swabs as assessed by the Tag4 assay and fourteen of
those by the SOLiD assay.
Results
We have published the design of our molecular probes
(Figure 1a) and our assay procedure [2]. These are reca-
pitulated in the Methods section.
Simulated clinical samples
Our earlier work with simulated clinical samples
proved critical for development of the molecular probe
technology as assayed on Tag4 arrays [2]. Therefore,
we employed the same simulated clinical samples and
assayed them by SOLiD sequencing. Table 1 presents
the results. When assayed by SOLiD sequencing
(Table 1), there were no false negatives and one false
positive. Importantly, Lactobacillus acidophilus was
correctly found in SCA. With further regard to Lacto-
bacillus for the five simulated clinical samples,
the molecular probes for L. brevis were positive for
o n l yS C C ,t h es o l es a m p l ec o n t a i n i n gL. brevis.T h eL.
gasseri probes were positive for the three simulated
clinical samples containing L. gasseri (SCB, SCC, SCE)
and falsely positive for one more (SCA). Although not
s h o w ne x p l i c i t l yi nT a b l e1 ,w ec o u n t e dal a r g en u m -
ber of bacteria correctly negative for each of the five
Figure 1 Molecular probe design.( a) The deep blue color represents the 40-base sequence similarity domain (the Homer), which is divided
into two 20-base segments. The aquamarine color represents the 20-base oligonucleotide barcode from the Tag4 array. The yellow color
represents the 36-base domain for the two 20 base PCR primers. The two 20 base primers overlap by 4 bases at the 5’ ends. The total length is
96 bases. The 5’ end is phosphorylated. (b) The molecular probe mixture is incubated with the denatured target DNA under annealing
conditions. Where sufficient sequence similarity exists between the molecular probe and the target single-stranded DNA (indicated by the deep
blue color), 40 bp of duplex DNA are formed. The 5’-phosphorylated end of the molecular probe is adjacent to the 3’-hydroxyl end of the probe
with no bases missing.
Table 1 The composition of the five simulated clinical
samples and the detection of bacteria in each
Genome/
Mixture
ABCDE
12 312 312 312 312 3
A.
baumannii
1.75 11 0 0 3.5 11 3.5 11 00
B. fragilis 0 0 1.8 11 0 0 1.8 11 00
B. longum 10.0 11 00 00 00 00
E. coli 2.25 11 0 0 0 0 0 0 0.45 11
L.
acidophilus
10.0 0 1 00 00 00 00
L. brevis 0 0 0 0 10.0 11 00 00
L. gasseri 0 1 10.0 11 1.6 11 0 0 1.6 11
S. aureus 0 0 2.2 11 0 0 10.0 11 00
S.
agalactiae
0 0 2.4 11 0 0 10.0 11 00
T. pallidum 0.3 11 0 0 3.0 11 0 0 10.0 11
The five simulated clinical samples are labeled A-E. Columns 1: Genomic DNA
concentration, ng/μl. Columns 2: Tag4 results. Columns 3: SOLiD results. In
columns 2 and 3, “1“, a majority of the molecular probes for that genome was
positive. “0”, a majority of the molecular probes for that genome was not
positive
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Page 2 of 10simulated clinical samples: SCA, 31 correct negatives;
SCB, 33; SCC, 33; SCD, 32, SCE, 34.
Within the Tag4 data, we found one false negative
and no false positives. The false negative was for L.
acidophilus in simulated clinical sample A (SCA). Two
of the four L. acidophilus molecular probes were posi-
tive for SCA. Since 50% is not a majority, we could
not call L. acidophilus present. None of the four L.
acidophilus molecular probes was positive for any of
the other four simulated clinical samples, not even
when two other members of the same genus, L. brevis
and L. gasseri,w e r ep r e s e n t :t h a ti s ,t h e r ew a sn o
cross-reaction. For each of the five simulated clinical
samples, we counted a large number of bacteria cor-
rectly negative: SCA, 34 correct negatives; SCB, 35;
SCC, 36; SCD, 35, SCE, 36.
Taken as a whole, the results for the simulated clini-
cal samples and the two assays (Tag4 and SOLiD)
were in excellent qualitative agreement. However,
quantitative agreement between the two methods was
not as good. As an example, the SOLiD assay for SCB
is shown in Figure 2. (The analogous data for the
other four simulated clinical samples are shown in
Additional file 1: Figures S1-S4.) The molecular probe
leading to the most sequence reads was for Streptococ-
cus agalactiae DNA. This number was dramatically
different from the number of sequence reads for the
second S. agalactiae probe (Figure 2). The second
highest number of sequence reads was for one molecu-
lar probe for Bacteroides fragilis DNA. However, B.
fragilis DNA was present in the least amount of the
four genomic DNAs (Figure 2).
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Figure 2 Quantitative data for the SOLiD assay for simulated clinical sample B (SCB). The red crosses indicate the known concentrations
of each genomic DNA (right ordinate). The horizontal lines indicate the number of sequence reads for each individual molecular probe (left
ordinate). Individual bacteria are listed alphabetically across the abscissa.
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Page 3 of 10Clinical samples
Our sole criterion for determining which clinical sam-
ples (vaginal swabs/DNAs) would be pursued in molecu-
lar probe studies was the availability of the DNA after
BigDye-terminator (Sanger) sequencing [5]. There was
sufficient DNA from twenty-one vaginal swabs to pur-
sue the molecular probe method as assayed on Tag4
arrays. Of these, there were fourteen DNAs sufficient to
additionally pursue the molecular probe method as
assayed by SOLiD sequencing.
The complete results for all swabs are given in Table
S2 (Additional file 1). We present three examples here
(Table 2). For clinical sample A08-2, BigDye-terminator
sequencing of the 16S ribosomal RNA gene (rDNA)
identified two bacteria for which there were molecular
probes: L. crispatus and L. jensenii, in substantially dif-
ferent amounts (Table 2). The same two bacteria were
also identified by molecular probe technology as assayed
on both Tag4 arrays and by SOLiD sequencing. Based
upon the BigDye-terminator data, neither assay pro-
duced false negatives or false positives with this clinical
sample. (We cannot distinguish the L. jensenii probes
hybridizing with L. jensenii DNA, cross-hybridizing with
L. crispatus DNA, or both.) Thirty-seven and thirty-
eight bacteria were correctly negative with the Tag4 and
SOLiD assays, respectively.
For clinical sample A10-4 (Table 2), BigDye-termina-
tor sequencing of rDNA identified two bacteria for
which there were molecular probes: L. crispatus and L.
gasseri, in substantially different amounts. Both assays
detected L. crispatus, but neither assay detected L. gas-
seri.C l e a r l y ,t h eL. gasseri molecular probes had not
cross-reacted with L. crispatus DNA. We assume that
the amount of L. gasseri DNA in clinical sample A10-4
was below the minimum detection limit of the molecu-
lar probes, although the minimum detection limit of the
molecular probes in clinical samples has not been deter-
mined and was probably different for each probe [2].
(The same assumption has been made in an additional
six cases: four with the Tag4 assay and two with the
SOLiD assay.) Thirty-seven and thirty-eight bacteria
were correctly negative with the Tag4 and SOLiD assays,
respectively.
Clinical sample A22-3 presents a more complicated
picture (Table 2). Both assays correctly identified L. cris-
patus and L. jensenii DNAs. However, the Tag4 assay
identified Enterococcus faecalis DNA, and the SOLiD
assay identified Treponema pallidum DNA as being pre-
sent. Nevertheless, thirty-six and thirty-seven bacteria
were correctly negative with the Tag4 and SOLiD assays,
respectively.
The qualitative agreements between the BigDye-termi-
nator and Tag4 data and the BigDye-terminator and
SOLiD data are shown in Table 3. For the twenty-one
swabs for which there were Tag4 data, thirteen (62%)
were in complete agreement with the BigDye-terminator
data. For the fourteen swabs for which there were
SOLiD data, 8 (57%) were in complete agreement with
the BigDye-terminator data. Five (24%) swabs had
apparently false positives b yt h eT a g 4a s s a ya n dt h r e e
(21%) by the SOLiD assay. There was no coordination
of the apparently false positives between the two assays.
As examples, A16-4 had five false positives by the Tag4
assay while the SOLiD assay produced none. A01-1 had
four false positives by the SOLiD assay while the Tag4
assay produced none.
The false negative category was impacted by the unde-
terminable minimum detection limits for each molecular
probe. As an example, for A10-2, the presence of Cory-
nebacterium glutamicum was supported by < 1% of the
BigDye-terminator reads (Additional file 1: Table S2).
Not one of the three C. glutamicum molecular probes
was positive in either the Tag4 or the SOLiD assay.
Leaving aside those seven negatives that are probably
explained by the minimum detection limit (Additional
file 1: Table S2), there remained five false negatives: 3
(14%) from the Tag4 assay and 2 (14%) from the SOLiD
assay. There was no coordination between the two
assays. As an example, L. gasseri was supported by > 2%
of the BigDye-terminator reads for seven swabs. For five
of these (A03-2, A07-1, A16-2, A16-3, A17-3), all assays
were positive for L. gasseri and were in agreement
(Additional file 1: Table S2). A07-2 was falsely negative
Table 2 Clinical samples: comparison of BigDye-
terminator reads, Tag4 fluorescent signals, and SOLiD
reads.
A08-2
Bacterium BigDye-terminator reads (%) Probes/Tag4 Probes/SOLiD
L. crispatus 95% 1 1
L. jensenii <1 % 1 1
A10-4
Bacterium BigDye-terminator reads (%) Probes/Tag4 Probes/SOLiD
L. crispatus 89% 1 1
L. gasseri <1 % 0 0
A22-3
Bacterium BigDye-terminator reads (%) Probe/Tag4 Probe/SOLiD
E. faecalis 10
L. crispatus 86% 1 1
L. jensenii 13% 1 1
T. pallidum 01
The BigDye-terminator data are from [5]. For the purposes of this table, those
bacteria whose presence was supported by less than ten BigDye-terminator
reads have been ignored. Novel bacteria and bacteria without a public
genome sequence have also been ignored because they cannot be detected
by the molecular probes. “1”, a majority of molecular probes for this genome
was positive. “0”, a majority of molecular probes for this genome was not
positive
Hyman et al. BMC Microbiology 2012, 12:29
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Page 4 of 10for L. gasseri by the Tag4 assay, but correctly positive by
the SOLiD assay (Additional file 1: Table S2). In the for-
mer case, three of six (not a majority) of the L. gasseri
molecular probes were positive. For A03-3, none of the
six L. gasseri molecular probes was positive on the Tag4
array (Additional file 1: Table S2). This last result
remains an anomaly. The number of correctly negative
bacteria was also important. For the sample with the
most apparently false positive Tag4 identifications, A16-
4, nevertheless, thirty-one bacteria were correctly nega-
tive (Additional file 1: Table S2). For the sample with
the most apparently false positive SOLiD identifications,
A01-1, nevertheless, thirty-two bacteria were correctly
negative (Additional file 1: Table S2).
The large number of SOLiD reads and the high fluor-
escent intensities on the Tag4 arrays allowed the calcu-
lation of Pearson’s correlation coefficient between the
two assays and between each assay and the number/per-
cent of BigDye-terminator reads. Pearson’s correlation
coefficient ranges from 1 to -1 and represents a quanti-
tative comparison. The results are shown in Table 4.
There were thirteen comparisons of the SOLiD data to
the Tag4 data. Eleven (85%) of the coefficients were >
0.5, and nine (69%) of the coefficients were equal to, or
greater than, 0.7. There were twelve comparisons of the
SOLiD data to the BigDye-terminator data. Seven had a
correlation coefficient of 1, and one had a correlation
coefficient of 0.84, for a total of 66%. There were seven-
teen comparisons of the Tag4 data to the BigDye-termi-
nator data. Eleven had a correlation coefficient of 1, and
three had a correlation coefficient of > 0.9 for a total of
82%. Thus, overall, the quantitative correlations were
excellent.
Discussion
Every technology has its advantages and disadvantages.
There are two important challenges in detecting bacteria
by amplifying and BigDye-terminator (Sanger) sequen-
cing rDNA. (1) rDNA genes are present at multiple
copies per genome, and the copy number differs among
bacteria [6,7]. (2) The “universal” primers have mis-
matches to the rDNAs of highly relevant bacteria [8,9].
The negative impact of mismatch between primer and
template is substantial [9,10]. Baker et al. [11] found
that no primer pair had good matches to all bacterial
rDNA. Therefore, bacterial genomes with few ribosomal
RNA genes and/or with rDNA sequence mismatch to
the primers will likely be under-represented in the
sequencing library. The same considerations make
determining the minimum detection limit problematic.
In earlier work, we accomplished extensive modeling of
the cost/benefit ratio for BigDye-terminator sequencing
[12]. We concluded that four 96-well plates of sequence
reads maximized the cost/benefit ratio, which is what
we accomplished for these vaginal swabs: 4 × 96 = 384
Table 3 Qualitative agreement of Tag4 and SOLiD assays
with BigDye bacteria identifications
ID BigDye vs. Tag4 BigDye vs. SOLiD
A01-1 A B
A03-2 A C
A03-3 C
A07-1 A C
A07-2 C B
A08-2 A A
A10-2 B B
A10-4 A A
A12-2 A
A13-4 A
A16-2 A
A16-3 A
A16-4 B A
A17-3 A A
A19-4 B A
A20-3 A A
A22-3 B B
A23-1 A
A24-1 C
A25-2 B A
A27-2 A A
A, agreement; B, one (or more) false positive; C, one (or more) false negative;
blank: insufficient amount of sample to undertake SOLiD sequencing. In all
cases, bacteria inferred to be present, but at a concentration below the
minimum detection limit of the molecular probe technology, have been
ignored. Only those bacteria for which there were molecular probes were
considered
Table 4 Pearson correlation coefficients among the
assays
ID SOLiD vs. Tag4 SOLiD vs. BigDye Tag4 vs. BigDye
A01-1 0.74 1 1
A03-2 0.45 - 1 1
A03-3 1
A07-1 0.54 - 0.27 - 0.13
A07-2 0.70 - 0.28 - 0.19
A08-2 0.87 1 0.97
A10-2 0.90 1 1
A10-4 0.78 1 1
A13-4 1
A16-2 1
A16-4 0.57
A17-3 0.46 - 0.13 0.18
A19-4 0.88 1 1
A20-3 1
A22-3 0.76 1 0.95
A23-1 0.97
A25-2 0.83 0.84 1
A27-2 0.88 1 1
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Page 5 of 10(minus ~ 5% failed reads = 365 reads). BigDye-termina-
tor sequencing has a very low error rate. Nevertheless,
our rule-of-thumb is to require 10 BigDye-terminator
reads (~ 3% of the sequence reads) to securely detect a
bacterium.
Our molecular probe technology requires a reasonably
secure genome sequence for each bacterium and the
synthesis of long oligonucleotides. Second generation
sequencing is providing bacterial genome sequences fas-
ter and cheaper than BigDye-terminator sequencing.
The cost of synthesizing oligonucleotides is coming
down, while the length is going up.
For the molecular probes, the Homers are based upon
single copy sequences. Thus, unlike rDNA-based detec-
tion, there is no copy number variation among bacterial
genomes that could confound the results. However, to
design the Homers, we started with complete genome
sequences of specific strains of any given bacterial spe-
cies. The bacterial genome sequence section of GenBank
(presumably) contains only a fraction of the genome
sequences of all of the strains for any given species.
Thus, a molecular probe may be correctly positive for
one strain’s genome and correctly negative for another’s.
This situation would give rise to false negatives in
detecting bacteria. We have attempted to minimize this
possibility by employing multiple probes per genome
and with Homers derived from different parts of the
genome sequence.
We have employed two very different assays for the
molecular probes: Tag4 array and SOLiD sequencing.
There was an apparent lack of good, relative quantita-
tion for both assays, as seen for the simulated clinical
samples. With the Tag4 assay, fluorescence intensity is
an exponential function of mass and, thereby, inherently
difficult to quantitate. However, the assay for each sam-
ple requires an individual Tag4 array, and, therefore,
each Tag4 assay is independent of the other Tag4
assays. The SOLiD assay requires only counting the
number of reads supporting the presence of each bacter-
ium. However, as with any multiplex sequencing, the
samples are not independent, as there is a limit to the
total number of reads.
Our goal is to produce a technology that will detect
bacteria without culture, with commercially available
reagents, highly multiplexed, and that will ultimately
be fast and inexpensive. Other investigators have
invented or adapted technologies toward likely the
same goal. Several examples follow. The Insignia sys-
tem is closest to our technology [13,14]. The system is
in two parts. The first part is the publically available
software that defines oligonucleotides unique to the
target genome of interest [13]. The second part is a
quantitative PCR assay (qPCR) [14]. The software is
definitely useful. The qPCR assay cannot be
multiplexed. Nikolaitchouk et al. [15] applied “checker-
board DNA-DNA hybridization” to detect the microbes
in the human female genital tract and achieved a 13-
plex reaction. Given the complexity of this technology,
it is unlikely that very high multiplex can be achieved.
DeSantis et al. [16] designed and successfully
employed a microarray containing 297,851 oligonu-
cleotide probes derived from the rDNA of 842 subfa-
milies of prokaryotes. Willenbrock et al. [17] designed
and tested a microarray that contained genome
sequences from seven Escherichia coli genomes. Their
microarray is not commercially available and is unli-
kely to accommodate very high multiplexing. Dumon-
ceaux et al. [18] coupled microbe-specific
oligonucleotides to fluorescently labeled microspheres
and detected and counted the fluors by flow cytometry,
achieving a 9-plex reaction. At present, it is not clear
which, if any, of these technologies will turn out to be
widely used for detecting bacteria.
While we have concentrated on the detection and
identification of bacteria, our molecular probe technol-
ogy is not limited to that function. Archaea, viruses,
even individual genes (such as antibiotic-resistance
genes or bacterial toxin genes), could also be detected.
The only requirement is sufficient genome sequence to
d e s i g nt h eu n i q u es e q u e n c es i m i l a r i t yr e g i o no ft h e
molecular probe. Because of the multiplex nature of
both assays for the molecular probe technology, thou-
sands more probes, representing thousands more enti-
ties, may be added at any time [4]. Eventually, the entire
human microbiome, in health and in disease, may be
assayed in a single reaction tube and employing only
commercially available reagents.
Conclusions
We have presented the first use of our molecular probe
technology to detect bacteria in clinical samples. In
addition to the Tag4 array assay, we introduced a sec-
ond assay employing SOLiD sequencing. The SOLiD
sequencing assay allowed the processed samples to be
combined before sequencing for even greater multiplex-
ing. The correlations among those two assays and the
previously published BigDye-terminator sequencing
assay were excellent.
Methods
Human subjects
We have published the relevant information concerning
the patients who were recruited and consented for this
study [5]. All patients were enrolled at the University of
California, San Francisco (U.C.S.F). This protocol was
approved by the Committee on Human Research at U.
C.S.F and by the Committee on the Use of Human Sub-
jects in Research at Stanford University.
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Swabs of the posterior vaginal fornix were taken at U.C.
S.F., as described [12]. The frozen, de-identified vaginal
swabs were transferred to the Stanford Genome Tech-
nology Center (S.G.T.C.). We purified total DNA from
each vaginal swab employing a Qiagen DNeasy Blood
and Tissue Kit. The final step was dialysis and concen-
tration with Amicon Ultra Centrifugal Filters (0.5 ml,
100 K). Each total DNA preparation for each swab was
frozen at-70°C in two ~10 μl aliquots until use.
BigDye-terminator sequencing to detect the bacteria
present on the swabs
We have published our procedures for PCR amplifying
and cloning the rDNA genes, and sequencing the rDNA
genes employing BigDye-terminator chemistry (Sanger
sequencing) [12]. In brief, we achieved four 96-well
plates of sequence reads per swab [5]. We assembled
the individual sequence reads into contigs employing
the KB Basecaller [19]. Importantly, we hand edited the
contigs. We compared the consensus sequence of each
contig to the data in the Ribosomal Database Project
[ R D P ;[ 2 0 ] .T e c h n i c a l l y ,t h eannealing of a molecular
p r o b et oat e m p l a t eo n l yc o n f i r m e dt h ep r e s e n c eo fa
particular sequence. We inferred the presence of a parti-
cular bacterium from the similarity of any given contig
consensus sequence to its closest match in the RDP.
Molecular probes
We have published the detailed design of our molecular
probes [2]. In brief, there are three domains within the
molecular probes (Figure 1a). The first domain is a con-
tiguous 40-base sequence (the “Homer”), divided into
two 20-mers, unique to the genome of the target bac-
teria. A list of the bacteria and their corresponding gen-
ome sequences is provided in (Additional file 1: Table
S3) [21]. The second domain is a twenty base oligonu-
cleotide barcode from the Affymetrix Tag4 array [22].
The third domain is a 36-base universal PCR amplifica-
tion sequence [23]. Thus, the molecular probes are 96
bases in length. We purchased the probes as 5’-phos-
phorylated and PAGE-purified from Integrated DNA
Technologies. The molecular probe mixture contained
192 molecular probes representing 40 bacteria [2].
There was an average of (192/40 =) 4.8 molecular
probes per bacterial genome with a range of 2-to-7.
Our procedure is to anneal the molecular probes to
the denatured DNA target. Where there is sufficient
sequence similarity between probe and target, a circular
DNA forms (Figure 1b). No bases are missing. Only a
phosphodiester bond is missing between the 5’ and 3’
bases of the probe. Enzymatic ligation produces single-
stranded circular DNA. Exonuclease digestion removes
all linear DNA. PCR primers based upon the 36-base
universal amplification sequence are employed to PCR
amplify the circular DNA.
For the purposes of this work, we excluded from the
analysis those bacteria with insufficient public genome
sequence to design molecular probes. This category
included novel bacteria, which were defined as pre-
viously [12]. The novel rDNA sequences have been
deposited in GenBank: accession numbers [HQ293151-
HQ293203].
Assaying the molecular probes on Tag4 arrays
T h eT a g 4a r r a yc o n t a i n s8 - μm features. Each 20-mer
barcode is replicated and dispersed five times on the
array [22]. We have published the detailed procedures
for assaying the molecular probes on the Tag4 array
[2]. In all cases, the final read-out was fluorescence
intensity.
On all the Tag4 arrays, the six molecular probes for L.
delbrueckii produced no signals above background
(unoccupied 20-mers on the Tag4 array). Therefore, we
employed these six probes as the negative controls. We
calculated the average fluorescence signal and standard
deviation for the six L. delbrueckii probes. To minimize
false positives at this stage of the development of the
molecular probe technology, we calculated the average
plus five standard deviations. We employed that number
as the cut-off between negative and positive for each
molecular probe on a Tag4 array. Also to minimize false
positives at this stage of the development of the molecu-
lar probe technology, we required concordance of the
data. A majority (> 50%) of the molecular probes for
any given bacterium must have been positive for us to
call a bacterium present. There is a potential problem
with this procedure that is related to possible strain var-
iation in genome sequence: i.e., genome sequence varia-
tion within the same species. Any given molecular probe
could be authentically positive for one strain and
authentically negative for another.
For the five simulated clinical samples, five molecular
probes were positive for all samples whether their corre-
sponding DNA was present or not: one probe each for
Acinetobacter baumannii (ED211; leaving four probes),
B. fragilis (ED141; leaving four probes), Bifidobacterium
longum ( E D 6 1 1 ;l e a v i n gf o u rp r o b e s ) ,a n dt w op r o b e s
for T. pallidum (ED317 and ED322; leaving three
probes). Therefore, the data from these five molecular
probes were excluded from the analyses. Two of three
probes for Gardnerella vaginalis (ED116 and ED121B)
were also positive for all five simulated clinical samples,
when there was no G. vaginalis DNA present in any
sample. Since we would not call a bacterium present or
absent on the basis of one molecular probe, G. vaginalis
was excluded from the analyses. What remained for
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molecular probes representing 39 bacteria.
We conducted an analogous process for detecting pro-
miscuous molecular probes within the Tag4 data for the
twenty-one clinical samples. Again, to minimize false
positives at this stage of the development of the molecu-
lar probe technology, we identified molecular probes
positive for ten or more (equal to, or greater than, 50%)
of the clinical samples (excluding Lactobacillus probes).
We abandoned the data therefrom: two probes for A.
baumannii (ED212 and ED213; leaving three probes)
were positive for twenty and nineteen samples, respec-
tively; two probes for G. vaginalis (ED116 and ED121B;
leaving one probe); two probes for Streptococcus pneu-
moniae (ED276 and ED277; leaving three probes) were
positive for twelve and thirteen samples, respectively;
one probe for S. pyogenes (ED413; leaving three probes)
was positive for ten samples; and one probe for Fuso-
bacterium nucleatum (ED559; leaving five probes) was
positive for seventeen sampl e s .T h ed a t af r o ma l ls i x
Enterobacter probes (leaving none) were excluded. G.
vaginalis and Pseudomonas aeruginosa were left with
only one molecular probe each. Since we would not
make a present/absent determination on the basis of
one molecular probe, G. vaginalis and P. aeruginosa
were removed from consideration within the clinical
samples. Only two promiscuous probes were shared
between both sets of Tag4 data: ED116 and ED121B (G.
vaginalis). Whereas one A. baumannii probe (ED211)
was promiscuous in the simulated clinical sample data,
two other A. baumannii probes (ED212 and ED213)
were promiscuous in the clinical sample data. What
remained for the authentic clinical samples assayed on
the Tag4 array were (192 - 17 =) 175 molecular probes
representing 37 bacteria.
Public genome sequence for L. crispatus and L. jense-
nii appeared only after the design of all of the other
molecular probes [2]. These two genome sequences
were derived from short shotgun pyrosequencing reads,
which had been assembled into dozens of contigs for
each genome. Thus, these two genome sequences were
far from ideal for the purpose of designing unique 40-
mer Homers. Nevertheless, given the importance of L.
crispatus and L. jensenii to the health of the human
vagina, we designed molecular probes for these two bac-
terial DNAs. Presumably, as a direct consequence of the
incompleteness of the two genome sequences, the mole-
cular probes for L. crispatus and L. jensenii cross-
reacted with each other’s DNA and sometimes with L.
brevis and L. gasseri DNAs as well. In addition, although
the sequences for the existing molecular probes for L.
brevis and L. gasseri were compared to the L. crispatus
and L. jensenii genome sequences with only negative
results, the L. brevis and L. gasseri probes sometimes
reacted with L. crispatus and L. jensenii DNAs in the
clinical samples. To avoid confusion, only those Lacto-
bacillus species identified by BigDye-terminator sequen-
cing appear in the tables. The probes for L. acidophilus,
L. delbrueckii,a n dL. plantarum did not cross-react
with other Lactobacillus DNAs.
The microarray data are MIAME compliant and have
been deposited in the Array Express website: accession:
[E-MEXP-2958]. The CEL (cell intensity) files of the
microarray data are publicly available on the Stanford
Genome Technology Center website http://med.stan-
ford.edu/sgtc/research/download/.
Assaying the molecular probes by Sequencing by
Oligonucleotide Ligation and Detection (SOLiD)
The primers used to amplify the product for SOLiD
sequencing are presented in Table S1 (Additional file 1).
The primer sequences were based upon published
designs [24].
SOLiD sequencing, a sequencing-by-ligation technol-
ogy (Applied Biosystems, Foster City, CA), was per-
formed at the University of California Santa Cruz
Genome Sequencing Center. We have published our
procedure for the library preparation of the samples for
SOLiD sequencing [25,26]. We followed the manufac-
turer’s protocols for the barcoded SOLiD System 3.0
Fragment Library. We prepared the samples according
to the manufacturer’s protocols for the emulsion PCR
step of SOLiD sequencing. We processed the samples
with the SOLiD Version 3.0 system, producing 50 bases
of sequencing information for each read.
Molecular tag sequences were ligated and amplified in
silico to create the expected reference sequences. The
forward and reverse complements of all molecular tag
reference sequences were translated from base space
into color space using a custom perl script. We trimmed
20 bases from the 5’ end of each read to remove the
adapter.
We aligned the sequence reads to each reference
molecular tag sequence using a publically available
Smith-Waterman local alignment in colorspace with
affine gap penalties [27]. We determined an alignment
threshold corresponding to an alpha value of 0.05 by
aligning 10 million random reads to each reference
sequence. For each read, we kept the reference sequence
with the highest scoring alignment if its score exceeded
the empirically derived threshold. The final read-out
was the number of reads corresponding to each molecu-
lar probe.
Analogously to the processing of the Tag4 data, we
e m p l o y e dt h ed a t af o rt h es i xp r o b e sf o rL. delbrueckii
as the negative control. The average number of SOLiD
reads and standard deviation for the six were calculated.
Again, to minimize false positives at this stage of the
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used the average plus five standard deviations as the
cut-off between negative and positive for each molecular
probe. Also to minimize the number of false positives at
this stage of the development of the molecular probe
technology, concordance of the data was required. A
majority of the molecular probes for any given microbe
must have been positive to score the microbe as present.
The same caveats as for the Tag4 data analysis apply.
We identified promiscuous molecular probes for the
five simulated clinical samples. ED116 (G. vaginalis) and
ED675 (L. jensenii) were positive for all five simulated
clinical samples, when neither DNA was present in any.
ED611 (B. longum) and ED121B (G. vaginalis)w e r e
positive for four of the five simulated clinical samples.
Therefore, the data from these four probes were
excluded from the analyses. As only one G. vaginalis
probe remained, G. vaginalis was removed from further
consideration. That left 187 molecular probes represent-
ing 39 bacteria.
There were SOLiD data for fourteen clinical samples.
Since these were sequenced with the simulated clinical
samples, the identical negative control was employed.
We identified promiscuous molecular probes for the
clinical samples. We excluded the data for any probe
positive for seven (50%) or more samples (except Lac-
tobacillus). That group included sixteen molecular
probes: A. baumannii (ED211, 13/14; ED212, 7/14;
ED213, 8/14; leaving two probes), B. fragilis (ED141,
12/14; leaving four probes), B. longum (ED611, 13/14;
ED614, 12/14; ED619, 7/14; leaving two probes), G.
vaginalis (ED116, 13/14; ED119, 10/14; ED121B, 14/14;
leaving no probes), L. jensenii (ED675, 14/14; leaving
five probes), Staphylococcus aureus (ED236, 12/14;
leaving two probes), S. agalactiae (ED263, 12/14; leav-
ing one probe), T. pallidum (ED317, 14/14; ED322, 9/
14; leaving three probes), and Ureaplasma urealyticum
(ED640, 12/14; leaving four probes). Unfortunately,
there were no remaining molecular probes for G. vagi-
nalis,a n dS. agalactiae was left with only one molecu-
lar probe. Since we would not make a present/absent
determination on the basis of one molecular probe, S.
agalactiae was removed from consideration within the
clinical samples. (Interestingly, the one remaining S.
agalactiae molecular probe, ED265, was never positive
for any sample.) What remained for the authentic clin-
ical samples were (192 - 17 =) 175 molecular probes
representing 38 bacteria.
The four promiscuous probes from the SOLiD data
for the simulated clinical samples were also promiscuous
within the clinical samples: ED116 and ED121B (G.
vaginalis), ED611 (B. longum), and ED675 (L. jensenii).
Overall, only two probes were promiscuous in all four
sets of data: ED116 and ED121B (G. vaginalis). ED611
(B. longum) was promiscuous in three of the four sets.
No other probes were that promiscuous.
Correlations
Bacterial species identified by BigDye-terminator
sequencing and by molecular barcodes were used to
investigate correlations among the two methods and
three assays. Raw CEL files were obtained for each Tag4
assay. The fluorescent intensity was calculated for each
molecular barcode. The number of reads from SOLiD
sequencing was counted for each barcode. We calcu-
lated Pearson’s correlation coefficient for samples
assessed by both SOLiD sequencing and Tag4 arrays.
For the “cut-off” method, we preserved the number of
counts for each probe only if that number exceeded the
number of counts for the negative control molecular
probes. For swabs A12-2, A16-3, and A24-1, less than
one bacterium was identified. Therefore, we could not
calculate the correlation coefficients for these three
samples.
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